A comprehensive review on the treatment approaches of multiple sclerosis: currently and in the future
- 3 September 2018
- journal article
- review article
- Published by Springer Science and Business Media LLC in Inflammation Research
- Vol. 68 (1), 25-38
- https://doi.org/10.1007/s00011-018-1185-0
Abstract
Multiple sclerosis (MS) is a chronic and autoimmune disease of the central nervous system (CNS), mainly characterized by inflammatory demyelination, which manifests as relapses and diffuse damage and brain volume loss, both accounting for neurodegeneration, and therefore, physical disability. MS typically affects young adults and is commonly diagnosed in the early years by acute relapses, which then followed through partial or complete remission period. The clinical course of MS is characterized as four major classifications, including relapsing–remitting (RRMS), primary progressive (PPMS), progressive relapsing (PRMS), and secondary progressive (SPMS).Keywords
This publication has 120 references indexed in Scilit:
- Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosisNeuropsychiatric Disease and Treatment, 2013
- Insufficient OPC migration into demyelinated lesions is a cause of poor remyelination in MS and mouse modelsActa Neuropathologica, 2013
- Role of oral teriflunomide in the management of multiple sclerosisNeuropsychiatric Disease and Treatment, 2013
- Human iPSC-Derived Oligodendrocyte Progenitor Cells Can Myelinate and Rescue a Mouse Model of Congenital HypomyelinationCell Stem Cell, 2013
- Oral available agents in the treatment of relapsing remitting multiple sclerosis an overview of merits and culpritsDrug, Healthcare and Patient Safety, 2013
- T Cell Vaccination Benefits Relapsing Progressive Multiple Sclerosis Patients: A Randomized, Double-Blind Clinical TrialPLOS ONE, 2012
- Oral Resveratrol Reduces Neuronal Damage in a Model of Multiple SclerosisJournal of Neuro-Ophthalmology, 2010
- Safety and Immunological Effects of Mesenchymal Stem Cell Transplantation in Patients With Multiple Sclerosis and Amyotrophic Lateral SclerosisArchives of Neurology, 2010
- Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetateMultiple Sclerosis Journal, 2010
- Regulatory CD56brightnatural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosisProceedings of the National Academy of Sciences of the United States of America, 2006